Definitive radiotherapy (RT) for prostate cancer (PC) with dose intensification and/or focal boosting has excellent oncologic outcomes, but many patients experience adverse events. Dose escalation to the whole prostate improves outcomes at the expense of increased late adverse events. Intraprostatic recurrence after definitive RT typically occurs at the site of the primary tumor, suggesting that dose to the site of the dominant lesion is an important predictor of future failure. The efficacy and safety of tumor-focused RT compared to that of standard RT for definitive treatment of localized PC has not been assessed. RadTARGET (RAdiation Dose TAiloRing Guided by Enhanced Targeting; NCT06990542) is a phase II randomized trial that aims to demonstrate superior safety of image-guided, tumor-focused RT compared to standard RT for acute genitourinary (GU) or gastrointestinal (GI) in the setting of definitive RT for intermediate- and high-risk PC. The study intervention is image-guided, tumor-focused RT with dose intensification of cancer visible on imaging and dose de-intensification to remaining prostate. Patients will be randomized to two arms: those who receive standard RT dose and those that receive tumor-focused RT. The study population will be patients with intermediate- or high-risk PC planning to undergo definitive RT with or without systemic therapy. The primary endpoint to compare between randomized arms is acute GU or GI grade ≥2 adverse events. Participant and study duration are 5 years and 8 years, respectively. RadTARGET will compare the efficacy and safety of tumor-focused RT to that of standard RT for definitive treatment of localized PC. We hypothesize that the tumor-focused approach will substantially reduce adverse events after prostate RT while retaining high efficacy. If this hypothesis is confirmed, we will conclude that a phase III randomized control trial is warranted to formally establish oncologic non-inferiority compared to the current standard of whole-gland dose escalation.
Clinical and translational radiation oncology. 2026 May 15*** epublish ***
Anna M Dornisch, Mariluz Rojo Domingo, Roberta Vezza Alexander, Christopher C Conlin, Son Do, Rana R McKay, Vitali Moiseenko, Michael A Liss, Jasmine Liu, Todd Pawlicki, Samuel Pena, Edmund M Qiao, Brent S Rose, Rhea Rupareliya, Ajay P Sandhu, Jessica Scholey, Steven N Seyedin, James J Urbanic, Lee-Jen Wei, Tyler M Seibert
Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA., Moores Cancer Center, University of California San Diego, La Jolla, USA., Department of Radiology, University of California San Diego, La Jolla, USA., Department of Urology, University of California San Diego, La Jolla, USA., Department of Radiation Oncology, University of California San Francisco, San Francisco, USA., Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA.